Glesby MJ - Search Results

1

Isolated hepatitis B core antibody is associated with HIV and ongoing but not resolved hepatitis C virus infection in a cohort of US women.

French AL, Operskalski E, Peters M, Strickler HD, Tien PC, Sharp GB, Glesby MJ, Young M, Augenbraun M, Seaberg E, Kovacs A. French AL, et al. Among authors: glesby mj. J Infect Dis. 2007 May 15;195(10):1437-42. doi: 10.1086/515578. Epub 2007 Apr 5. J Infect Dis. 2007. PMID: 17436223 Free PMC article.

2

Granulocyte-macrophage colony-stimulating factor induces modest increases in plasma human immunodeficiency virus (HIV) type 1 RNA levels and CD4+ lymphocyte counts in patients with uncontrolled HIV infection.

Jacobson JM, Lederman MM, Spritzler J, Valdez H, Tebas P, Skowron G, Wang R, Jackson JB, Fox L, Landay A, Gilbert MJ, O'Neil D, Bancroft L, Al-Harthi L, Jacobson MA, Merigan TC Jr, Glesby MJ; National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. Jacobson JM, et al. Among authors: glesby mj. J Infect Dis. 2003 Dec 15;188(12):1804-14. doi: 10.1086/379899. Epub 2003 Dec 9. J Infect Dis. 2003. PMID: 14673758 Clinical Trial.

3

The effect of highly active antiretroviral therapy on dermatologic disease in a longitudinal study of HIV type 1-infected women.

Maurer T, Rodrigues LK, Ameli N, Phanuphak N, Gange SJ, DeHovitz J, French AL, Glesby M, Jordan C, Khalsa A, Hessol NA. Maurer T, et al. Clin Infect Dis. 2004 Feb 15;38(4):579-84. doi: 10.1086/381264. Epub 2004 Jan 30. Clin Infect Dis. 2004. PMID: 14765353

4

Prevalence of clinical symptoms associated with highly active antiretroviral therapy in the Women's Interagency HIV Study.

Silverberg MJ, Gore ME, French AL, Gandhi M, Glesby MJ, Kovacs A, Wilson TE, Young MA, Gange SJ. Silverberg MJ, et al. Among authors: glesby mj. Clin Infect Dis. 2004 Sep 1;39(5):717-24. doi: 10.1086/423181. Epub 2004 Aug 16. Clin Infect Dis. 2004. PMID: 15356788 Free PMC article.

5

Herpes zoster in women with and at risk for HIV: data from the Women's Interagency HIV Study.

Glesby MJ, Hoover DR, Tan T, Shi Q, Gao W, French AL, Maurer T, Young M, Dehovitz J, Ru J, Anastos K. Glesby MJ, et al. J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1604-9. doi: 10.1097/00126334-200412150-00013. J Acquir Immune Defic Syndr. 2004. PMID: 15577417

6

Pilot study of low-dose interleukin-2, pegylated interferon-alpha 2b, and ribavirin for the treatment of hepatitis C virus infection in patients with HIV infection.

Glesby MJ, Bassett R, Alston-Smith B, Fichtenbaum C, Jacobson EL, Brass C, Owens S, Sulkowski M, Race EM, Sherman KE; AIDS Clinical Trials Group A5088 Protocol Team. Glesby MJ, et al. J Infect Dis. 2005 Mar 1;191(5):686-93. doi: 10.1086/427812. Epub 2005 Jan 26. J Infect Dis. 2005. PMID: 15688281 Clinical Trial.

7

Effects of bacterial vaginosis and other genital infections on the natural history of human papillomavirus infection in HIV-1-infected and high-risk HIV-1-uninfected women.

Watts DH, Fazzari M, Minkoff H, Hillier SL, Sha B, Glesby M, Levine AM, Burk R, Palefsky JM, Moxley M, Ahdieh-Grant L, Strickler HD. Watts DH, et al. J Infect Dis. 2005 Apr 1;191(7):1129-39. doi: 10.1086/427777. Epub 2005 Feb 21. J Infect Dis. 2005. PMID: 15747249

8

Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus.

Marks KM, Petrovic LM, Talal AH, Murray MP, Gulick RM, Glesby MJ. Marks KM, et al. Among authors: glesby mj. J Infect Dis. 2005 Dec 1;192(11):1943-9. doi: 10.1086/497608. Epub 2005 Nov 2. J Infect Dis. 2005. PMID: 16267765

9

Factors associated with poor immunologic response to virologic suppression by highly active antiretroviral therapy in HIV-infected women.

Vaamonde CM, Hoover DR, Anastos K, Tan T, Shi Q, Gao W, Kovacs A, Cohen M, DeHovitz J, Glesby MJ. Vaamonde CM, et al. Among authors: glesby mj. AIDS Res Hum Retroviruses. 2006 Mar;22(3):222-31. doi: 10.1089/aid.2006.22.222. AIDS Res Hum Retroviruses. 2006. PMID: 16545008 Free PMC article.

10

A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086.

Benson CA, Vaida F, Havlir DV, Downey GF, Lederman MM, Gulick RM, Glesby MJ, Wantman M, Bixby CJ, Rinehart AR, Snyder S, Wang R, Patel S, Mellors JW; ACTG A5086 Study Team. Benson CA, et al. Among authors: glesby mj. J Infect Dis. 2006 Nov 1;194(9):1309-18. doi: 10.1086/508289. Epub 2006 Sep 22. J Infect Dis. 2006. PMID: 17041858 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

203 results

Search Page

Filters